Clinical Trials

The purpose of this study is to study the sexuality and quality of life (QOL) gap in post-transplant patient care and develop an action plan addressing both the gaps in research and clinical care of this group of patients.

The purpose of this study is to evaluate safety and efficacy outcomes in renal transplant recipients in whom post-transplant care is managed using AlloSure®. AlloSure® is a non-invasive test to measure donor-derived cell-free DNA (dd-cfDNA). The AlloSure test is intended to assess the probability of allograft rejection in kidney transplant recipients with clinical suspicion of rejection and to inform clinical decision-making regarding the necessity of renal biopsy in such patients at least 2 weeks post-transplant in conjunction with standard clinical assessment. Amendment 1 (A1): Is an observational study to develop and validate the clinical use of KidneyCare®.

The purposes of this study are to prospectively evaluate the effects of a structured, modified Mediterranean diet on post-liver transplant weight gain and development of PTMS, to prospectively evaluate the effects of a structured, modified Mediterranean diet on cardiovascular outcomes post-liver transplantation, and to prospectively evaluate the effects of a structured, modified Mediterranean diet on development or recurrence or de novo NAFLD/NASH in liver-transplant patients.

The purpose of this study is to evaluate KidneyCare (AlloSure, AlloMap kidney and iBox) in patients with negative c4d microvascular inflammation (MVI) with or without Donor-Specific Antibodies (DSA) as compared to cohort with normal biopsies without DSA.

Nonadherence to immunosuppression is associated with an increased risk for organ rejection, allograft vasculopathy, and death (De Geest et al., 2014). Immunosuppression nonadherence has been found to be a factor in up to 90% of late acute rejection events that occur after the first year following transplant, and in 13% to 26% of deaths among heart transplant recipients in single-center research studies (De Geest et al., 2005). A prospective cohort study found that for individuals who were nonadherent after their first year following transplant, the risk of a negative clinical event was doubled (Dobbels et al., 2004). In ...

The purpose of this study is to describe the association between Prospera dd-cfDNA measures and other diagnostic tests used to detect heart allograft rejection and/or njury, including histology, echocardiography and DSA, in the first post-transplant year. Additionally, to inform rates of clinical outcomes in a contemporary cohort of adult heart transplant recipients to determine power for a future randomized, controlled clinical trial.